Uganda
![May/June 2022: Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial](https://icap.columbia.edu/wp-content/uploads/injection-1080x675.jpg)
May/June 2022: Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial
Article and Study Summary: Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial Published in: Lancet. 2022;399(10337):1779-1789 https://doi.org/10.1016/S0140-6736(22)00538-4 Authors: Delany-Moretlwe S, Hughes...![April 2022: Single-dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis](https://icap.columbia.edu/wp-content/uploads/unnamed-3-1080x675.jpg)
April 2022: Single-dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis
Article and Study Summary: Single-dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis Published in: New England Journal of Medicine 2022;386(12):1109-1120 https://www.nejm.org/doi/full/10.1056/NEJMoa2111904 Authors: Jarvis JN, Lawrence DS, Meya DB, et...![February 2022: Dolutegravir as First- or Second-line Treatment for HIV-1 Infection in Children](https://icap.columbia.edu/wp-content/uploads/istock1-1080x675.png)
February 2022: Dolutegravir as First- or Second-line Treatment for HIV-1 Infection in Children
Article and Study Summary: Dolutegravir as First- or Second-line Treatment for HIV-1 Infection in Children Published in: New England Journal of Medicine 2021,385(27):2531-2543. https://www.nejm.org/doi/full/10.1056/NEJMoa2108793 Authors: Turkova A, White E, Mujuru HA,...![January 2022: Multicomponent Strategy with Decentralized Molecular Testing for Tuberculosis](https://icap.columbia.edu/wp-content/uploads/Untitled-design-3-1-1080x675.png)